Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Will Merck (MRK) Stock Be Helped as Keytruda Meets Goal?

NEW YORK (TheStreet) -- Merck (MRK) has ended the trial for its immunotherapy Keytruda after a late-stage study met its primary goal.

Compared to standard chemotherapy, Keytruda improved the overall survival rate of people who previously underwent treatment for bladder cancer.

The drug has already been approved to treat a form of lung cancer, and generated $314 million in second-quarter sales.

Merck is scheduled to report 2016 third-quarter earnings before Tuesday's market open.

Analysts surveyed by FactSet are looking for...